Institutional Ownership
Kiniksa Pharmaceuticals Ltd
CUSIP G5269C101COMQ1 2026
13D / 13G Filings
26
Schedule 13D/13G on record
Beneficial Filers
11
Distinct reporting persons
Largest Stake
11.9%
Max % of class reported
Institutional Holders
2
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
26 filings · latest Feb 14, 2024
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 14, 2024 | Fairmount Funds Management LLC | 13G/A | 8.1% | 2.88M | SEC |
| 2 | Feb 14, 2024 | Hhlr Advisors, Ltd. | 13G/A | 9.9% | 3.88M | SEC |
| 3 | Feb 13, 2024 | Vanguard Group Inc | 13G/A | 8.4% | 2.97M | SEC |
| 4 | Feb 12, 2024 | Rubric Capital Management LP | 13G | 8.2% | 2.91M | SEC |
| 5 | Aug 18, 2023 | Hhlr Advisors, Ltd. | 13G/A | 9.9% | 3.54M | SEC |
| 6 | Aug 10, 2023 | Fairmount Funds Management LLC | 13G | 6.1% | 2.14M | SEC |
| 7 | Feb 14, 2023 | Hhlr Advisors, Ltd. | 13G/A | 7.6% | 2.62M | SEC |
| 8 | Feb 9, 2023 | Vanguard Group Inc | 13G/A | 9.3% | 3.23M | SEC |
| 9 | Feb 3, 2023 | Pictet Asset Management SA | 13G | 3.6% | 1.23M | SEC |
| 10 | Feb 14, 2022 | Ameriprise Financial Inc | 13G/A | — | — | SEC |
16 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Kiniksa Pharmaceuticals Ltd.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Uniplan Investment Counsel, Inc. | 493 | $23.7K |
| 2 | Harbor Capital Advisors, Inc. | 15.1K | $726 |